• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy
    Follow us on Twitter

      FDA reviewing safety of Actos diabetes drug

      Posted AtReuters.com

      The U.S. Food and Drug Administration said on Friday its has begun a safety review of diabetes drug Actos after receiving early results from a long-term study designed to evaluate the risk of bladder cancer in people treated with the drug.

      The early data showed an increased risk of bladder cancer in patients with the longest exposure to Actos and in those with the highest cumulative dose of the drug, the agency said in a statement.

      The FDA said the preliminary results are based on 5-year data from an ongoing 10-year trial by the drug's maker, Takeda Pharmaceutical Co Ltd.

      Actos is in the same class of drugs as GlaxoSmithKline PLC's Avandia, which has not been associated with bladder cancer but has been linked to heart risks.

      The FDA said patients should not stop taking Actos unless told to do so by their doctor.

      Sep 22, 2010


       

      Share this Article!

    Back to top^